AMGN

HealthJustices rule unanimously that Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted HealthJustices rule unanimously that Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials…

ShareListen(2 min) ShareListen(2 min) FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

A new Amgen Inc. lung-cancer treatment, Lumakras, carried a hefty price tag when it came out in 2021: $17,900 per patient monthly.Just over a year later, in December 2022, a second drug for the same type of cancer, Krazati from Mirati Therapeutics Inc., had an even higher price: $19,750 a month—a 10% premium. As drugmakers face rising pressure to rein in repeat or annual price hikes on existing drugs, new brand-name medicines are coming to market with ever-higher…

Pharmaceutical companies raised list prices of 983 arthritis, cancer and other prescription drugs by an average of 5.6% at the start of this year—restrained increases as the industry faces a new federal law aimed at lowering medicine costs. Pfizer Inc., Novartis AG and Eli Lilly & Co. are among the companies that took the price increases through Jan. 31, according to 46brooklyn Research, a nonprofit drug-pricing analytics group. In recent…

AbbVie Inc.’s ABBV 0.65% arthritis therapy Humira is set to face its first competition in the U.S. from a near-identical copycat, the end of the exclusive run of what was for years the country’s biggest-selling drug.After two decades of patent protection and more than $135 billion in U.S. sales, Humira will contend with the near-identical version from Amgen Inc. AMGN 0.17% starting Tuesday, Amgen said. Other Humira…

Pharmaceutical companies are grappling with the arrival in the U.S. of sweeping new legislation meant to blunt drug prices. The impact in 2023 may actually be higher drug prices. President Biden last year signed into law the bill dubbed the Inflation Reduction Act, empowering Medicare, the country’s biggest buyer of prescription drugs, to negotiate how much it pays for certain high-price therapies. Another provision set a cap on price increases that requires drugmakers to pay Medicare rebates on treatments whose prices…

Drugmakers in 2022 acquired companies with approved or thoroughly tested drugs, a strategy that could pay off faster than buying less-advanced treatments and help replenish revenue as top-selling products face competition from generics. Pfizer Inc. and Amgen Inc. are among cash-flush companies that bought makers of approved drugs for treating migraines, inflammation and other ailments. Bristol-Myers Squibb Co. and…

After holding fire during much of the pandemic, big pharmaceutical companies including Pfizer Inc. and Merck & Co. have been pulling the trigger on multibillion-dollar outlays for companies with approved products and technologies that can fuel new sales. To date, the companies have been making mostly small- and midsize deals, often for launched products, to avoid the challenges of digesting large rivals and limit the risks that an experimental drug doesn’t…

Amgen Inc. AMGN -2.42% is in advanced talks to buy drug company Horizon Therapeutics HZNP 0.39% PLC, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.The U.S. biotechnology company was the last of three suitors standing in an auction for Horizon, the people said, after French drugmaker Sanofi…

The Dow is beating the broader market to a degree not seen in nearly a century.The Dow Jones Industrial Average is down 5.3% this year, which isn’t normally a cause for celebration. But that performance looks downright golden compared with the broad S&P 500, which is off 15%, and the tech-heavy Nasdaq Composite, which has dropped 27%. The Dow’s year-to-date advantage over the S&P 500 is the biggest since 1933. The Dow’s lead over the Nasdaq at this point in the year is the widest since 2000. Of the three indexes,…